Research Analysts Issue Forecasts for TPST Q1 Earnings

Tempest Therapeutics, Inc. (NASDAQ:TPST) – Equities research analysts at HC Wainwright issued their Q1 2025 earnings estimates for Tempest Therapeutics in a report released on Friday, March 28th. HC Wainwright analyst J. Pantginis expects that the company will post earnings per share of ($0.34) for the quarter. HC Wainwright has a “Buy” rating and a $16.00 price target on the stock. The consensus estimate for Tempest Therapeutics’ current full-year earnings is ($1.39) per share.

Separately, Scotiabank decreased their target price on Tempest Therapeutics from $13.00 to $7.00 and set a “sector outperform” rating for the company in a research report on Friday.

Tempest Therapeutics Trading Down 4.4 %

Shares of NASDAQ TPST opened at $0.74 on Monday. The stock has a fifty day moving average price of $0.86 and a 200 day moving average price of $0.97. Tempest Therapeutics has a 12-month low of $0.70 and a 12-month high of $6.00. The company has a market cap of $32.21 million, a P/E ratio of -0.48 and a beta of -1.83.

Tempest Therapeutics (NASDAQ:TPST) last released its quarterly earnings data on Thursday, March 27th. The company reported ($0.31) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.24) by ($0.07). The firm had revenue of $0.49 million for the quarter.

Institutional Investors Weigh In On Tempest Therapeutics

A number of large investors have recently added to or reduced their stakes in the company. Millennium Management LLC purchased a new position in Tempest Therapeutics in the 4th quarter valued at about $158,000. Jane Street Group LLC acquired a new position in shares of Tempest Therapeutics in the fourth quarter worth about $411,000. Northern Trust Corp boosted its holdings in Tempest Therapeutics by 233.2% in the fourth quarter. Northern Trust Corp now owns 67,815 shares of the company’s stock valued at $57,000 after purchasing an additional 47,461 shares during the last quarter. XTX Topco Ltd grew its stake in Tempest Therapeutics by 570.3% during the 4th quarter. XTX Topco Ltd now owns 160,807 shares of the company’s stock valued at $134,000 after purchasing an additional 136,818 shares in the last quarter. Finally, Geode Capital Management LLC grew its stake in Tempest Therapeutics by 61.0% during the 4th quarter. Geode Capital Management LLC now owns 354,276 shares of the company’s stock valued at $296,000 after purchasing an additional 134,209 shares in the last quarter. 22.52% of the stock is owned by institutional investors and hedge funds.

Tempest Therapeutics Company Profile

Tempest Therapeutics, Inc, a clinical-stage oncology company, develops small molecule therapeutics that combine both tumor-targeted and immune-mediated mechanisms to treat various tumors. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, which is in a Phase 1 trial to treat cancer; and TPST-1120, a selective antagonist of peroxisome proliferator-activated receptor alpha that is in a Phase 1 trial for the treatment of solid tumors.